Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11379041 | 0.97 | — | — | |
| Methane SCHEMBL27405648 | 0.83 | — | — | |
| Methyl Alcohol SCHEMBL27522845 | 0.81 | — | — | |
| SCHEMBL11743492 | 0.80 | SHBG (0.46) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL5826116 | 0.77 | SHBG (0.43) | SHBGEPHX1CYP1A2 | |
| SCHEMBL3885036 | 0.76 | EPHX1 (0.40) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL8331279 | 0.75 | SHBG (0.41) | SHBGEPHX1CYP1A2 | |
| SCHEMBL27625255 | 0.74 | EPHX1 (0.44) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL8137256 | 0.74 | TP53 (0.41) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL6061503 | 0.74 | EPHX1 (0.56) | SHBGEPHX1TP53KDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3527600-B1 | ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER | ASAHI CHEMICAL IND (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-01-10 | — | — | US | disclosed |
| CN-109803992-B | Isocyanate composition and method for producing isocyanate polymer | 旭化成株式会社 | 2022-05-24 | — | — | CN | disclosed |
| CN-109843963-B | Isocyanate composition, method for producing isocyanate polymer, and isocyanate polymer | 旭化成株式会社 | 2022-05-13 | — | — | CN | disclosed |
| EP-3536683-B1 | POLYISOCYANATE COMPOSITION AND ISOCYANATE POLYMER COMPOSITION | ASAHI CHEMICAL IND (JP) | 2021-11-24 | — | — | EP | disclosed |
| US-11174337-B2 | Isocyanate composition, method for producing isocyanate polymer and isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-11-16 | — | — | US | disclosed |
| CN-107963982-B | Polyisocyanate composition and isocyanate polymer composition | 旭化成株式会社 | 2021-11-12 | — | — | CN | disclosed |
| EP-3372579-B1 | POLYISOCYANATE COMPOSITION AND ISOCYANATE POLYMER COMPOSITION | ASAHI CHEMICAL IND (JP) | 2020-10-28 | — | — | EP | disclosed |
| EP-2915803-B1 | POLYISOCYANATE COMPOSITION AND ISOCYANATE POLYMER COMPOSITION | ASAHI CHEMICAL IND (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| EP-1072596-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| US-5972962-A | Treatment of pruritus | PFIZER INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0938898-A2 | Treatment of pruritus | Pfizer Limited (GB) | 1999-09-01 | — | — | EP | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| EP-0882023-A1 | HISTAMINE H 3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997029092-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-08-14 | — | — | WO | disclosed |
| WO-1994024133-A1 | RING-SUBSTITUTED CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| US-4036896-A | FREE RADICAL CATALYST | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | IDH3A, IDH2, IDH3B | SHBG 2341/4885EPHX1 3187/4885TP53 2121/4885 |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | IDH3A, IDH2, IDH3B | SHBG 2249/4885EPHX1 3204/4885TP53 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.